Skip to main content

Abbott Laboratories (ABL.DE)

Frankfurt Stock Exchange (XETRA) Healthcare Medical - DevicesView data quality →
55.6Fair

ValueMarkers Composite Index

Top 59%#18,133 of 44,707
Overvalued

25% above intrinsic value ($69)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.85
Low Risk
Altman
4.40
Safe
DCF Value
$69
Overvalued
ROIC
8.4%
Adequate
P/E
26.9
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Abbott Laboratories (ABL.DE) — VMCI valuation read

Abbott Laboratories (ABL.DE) carries a VMCI composite of 56/100, 6 points above the Healthcare sector median of 50. Among mid-cap names, that gap places ABL.DE in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The ABL.DE insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads ABL.DE trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -0.9x leaves covenant headroom, the line to track on Abbott Laboratories's next 10-Q.

ABL.DE rose 2.6% over the trailing 7 days, with a +2.4% read on a 30-day basis.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

CEO: Robert Ford114,000 employeesUSwww.abbott.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ABL.DE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.